Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by cpacon Sep 03, 2020 4:04pm
568 Views
Post# 31505509

You could literally retire on ATE alone...

You could literally retire on ATE alone...Let's say you put $100k into ATE at the current market cap of $150MM today
5 years from now, if all goes according to plan, our lead drug will be on the market in the US and EU generating sales in the 100s of million with visibility of generating billions in revenues in a few short years from that...
Since pharma companies can be valued anywhere from 3-5x peak sales and our peak sales on just the lead drug is estimated at 5B, that would be a $15B market cap... or 100x today's values... even if you cut that in half to account for dilution along the way, you're talking about a 50x increase in your investment in a period of roughly 5 years... I think most people could retire comforably of $5 million, lol.
I'm looking to add another 100,000 shares, hopefully while prices hold at these levels....  

Wow.
Bullboard Posts